RxDoctor Payments Data

Yusuf Menda, MD

Nuclear Medicine · Iowa City, IANPI 1538157425

Payments from drug & device makers

No general payments reported

No drug or device maker reported general payments to this provider for 2019–2025. That is a common and unremarkable result.

$2,424,284in research payments, 2019–2025

Across 43 payments — averaging $56,379 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$1.7M
  • Progenics Pharmaceuticals, Inc.$585K
  • Advanced Accelerator Applications$70K
  • Clovis Oncology, Inc.$36K
  • Eli Lilly$24K

How this compares

Too few nuclear medicine providers in Iowato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$34,378
Medicare patients
376
Services billed
401

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other nuclear medicine in Iowa City

Where these figures come from

Is this you, or does something look wrong? →